- Home
- YHGJ vs RLMD Comparison
YHGJ vs RLMD Comparison
Compare YHGJ & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- RLMD
- Stock Information
- Founded
- YHGJ 1975
- RLMD 2004
- Country
- YHGJ United States
- RLMD United States
- Employees
- YHGJ N/A
- RLMD N/A
- Industry
- YHGJ Specialty Chemicals
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- RLMD Health Care
- Exchange
- YHGJ Nasdaq
- RLMD Nasdaq
- Market Cap
- YHGJ 22.5M
- RLMD 22.0M
- IPO Year
- YHGJ 1997
- RLMD N/A
- Fundamental
- Price
- YHGJ $0.83
- RLMD $0.61
- Analyst Decision
- YHGJ
- RLMD Buy
- Analyst Count
- YHGJ 0
- RLMD 3
- Target Price
- YHGJ N/A
- RLMD $5.00
- AVG Volume (30 Days)
- YHGJ 6.0K
- RLMD 378.6K
- Earning Date
- YHGJ 05-20-2025
- RLMD 08-06-2025
- Dividend Yield
- YHGJ N/A
- RLMD N/A
- EPS Growth
- YHGJ N/A
- RLMD N/A
- EPS
- YHGJ N/A
- RLMD N/A
- Revenue
- YHGJ $17,861,000.00
- RLMD N/A
- Revenue This Year
- YHGJ N/A
- RLMD N/A
- Revenue Next Year
- YHGJ N/A
- RLMD N/A
- P/E Ratio
- YHGJ N/A
- RLMD N/A
- Revenue Growth
- YHGJ 1.21
- RLMD N/A
- 52 Week Low
- YHGJ $0.43
- RLMD $0.24
- 52 Week High
- YHGJ $1.37
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- YHGJ 52.12
- RLMD 47.64
- Support Level
- YHGJ $0.73
- RLMD $0.59
- Resistance Level
- YHGJ $0.85
- RLMD $0.67
- Average True Range (ATR)
- YHGJ 0.08
- RLMD 0.07
- MACD
- YHGJ 0.01
- RLMD -0.01
- Stochastic Oscillator
- YHGJ 64.00
- RLMD 38.22
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.